HCM — HUTCHMED (China) Share News
0.000.00%
- £1.96bn
- £1.00bn
- $548.51m
Announcement pursuant to AIM Rule 17 Schedule 2(g)
Orpathys+Tagrisso improved PFS & OS in EGFRm lung
HK's Hutchmed rises on progress of Orpathys Plus Tagrisso for cancer treatment
Brief: Hutchmed (China) Says Orpathys Plus Tagrisso Improves Survival In Egfr-Mutated Nsclc In Phase III Trial
HUTCHMED Reports 2026 Interim Results
HUTCHMED climbs after China approves ORPATHYS for gastric cancer treatment
Brief: HUTCHMED (China) Announces NMPA Conditional Approval For Orpathys For Met-Amplified Advanced Gastric Cancer In China
HUTCHMED Announces NMPA Approval for ORPATHYS
Hutchmed To Announce 2026 Half: Year Results
HUTCHMED Highlights Phase II Data at ESMO
HUTCHMED Highlights Sovleplenib Phase III Data
AIM - AIM Notice - 11/06/2026
Block Admission Application
Unit of China's Haisco, Eli Lilly sign collaboration, licensing deals
HUTCHMED Highlights Data to be Presented at ASCO
NMPA approval for ELUNATE with TYVYT
Brief: Hutchmed (China) Announces NDA For Sovleplenib Accepted With Priority Review By NMPA
HUTCHMED Announces NDA Acceptance in China
2025 Annual Report and Notice of AGM